The Role of Molecular Imaging in Drug Discovery and Development
Abstract
Molecular imaging biomarkers are playing an increasingly important role in efforts to increase the probability of success of drug candidates by helping to validate novel drug targets in support of proof‐of‐concept testing early in the drug discovery and development process. By facilitating better and faster decision‐making, molecule and mechanism–based failures can be identified and eliminated from a research portfolio early in development thereby focusing research efforts on the best drug candidates and therapeutic hypotheses. Molecular imaging can be used to improve the cost‐effectiveness of studying unprecedented mechanisms, decrease cycle time, and improve drug pipeline quality.
Clinical Pharmacology & Therapeutics (2008); doi:10.1038/sj.clpt.6100467
Number of times cited: 9
- Shayne Cox Gad, USE OF IMAGING, IMAGING AGENTS, AND RADIOPHARMACEUTICALS IN NONCLINICAL TOXICOLOGY, Drug Safety Evaluation, (503-521), (2017).
- RJ Hargreaves, J Hoppin, J Sevigny, S Patel, P Chiao, M Klimas and A Verma, Optimizing Central Nervous System Drug Development Using Molecular Imaging, Clinical Pharmacology & Therapeutics, 98, 1, (47-60), (2015).
- Xi Yang, William B. Mattes, Qiang Shi, Zuquan Weng and William F. Salminen, Cell‐free microRNAs as Biomarkers in Human Diseases, microRNAs in Toxicology and Medicine, (363-387), (2013).
- Sandra M. Sanabria Bohorquez, Nicholas van Bruggen and Jan Marik, Developing Targeted PET Tracers in the Era of Personalized Medicine, Medicinal Chemistry Approaches to Personalized Medicine, (289-342), (2013).
- Vanessa N. Barth, Elizabeth M. Joshi and Matthew D. Silva, Target Engagement for PK/PD Modeling and Translational Imaging Biomarkers, ADME‐Enabling Technologies in Drug Design and Development, (493-511), (2012).
- Indranil Rao, HK Vinay and Sandhya Mandlekar, Pharmacodynamics, Encyclopedia of Drug Metabolism and Interactions, (1-51), (2012).
- Jonathan B. Moody, Philip S. Murphy and Edward P. Ficaro, Imaging as a Localized Biomarker: Opportunities and Challenges, Pharmaceutical Sciences Encyclopedia, (1-57), (2010).
- Andreas Reichel, Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept, Chemistry & Biodiversity, 6, 11, (2030-2049), (2009).
- N Petrick, DG Brown, O Suleiman and KJ Myers, Imaging as a Tumor Biomarker in Oncology Drug Trials for Lung Cancer: The FDA Perspective, Clinical Pharmacology & Therapeutics, 84, 4, (523-525), (2008).
